prednisone has been researched along with panobinostat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Ballanti, S; Bringhen, S; Corvatta, L; Liberati, AM; Offidani, M; Pulini, S | 1 |
| Abd-El Ghafaar, DM; Abdelsalam, M; Eid, R; El Wakeel, GA; El-Sabbagh, AM; El-Shenbaby, I; Elmarghany, EB; Haleem, AA; Hamdy, N; Hammad, A; Korkor, MS; Morsy, AI; Yassin, NA | 1 |
2 trial(s) available for prednisone and panobinostat
| Article | Year |
|---|---|
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Panobinostat; Prednisone; Recurrence; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prednisone; Prognosis; Survival Rate; Thalidomide | 2018 |
2 other study(ies) available for prednisone and panobinostat
| Article | Year |
|---|---|
Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Hematology; Humans; Hydroxamic Acids; Indoles; Lymphoma; Panobinostat; Prednisone; Rituximab; Vincristine | 2006 |
In vitro evaluation of the potential immunosuppressive effect of panobinostat on cultured lymphocytes retrieved from childhood systemic lupus erythematosus patients.
Topics: Annexin A5; Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lymphocytes; Panobinostat; Prednisone | 2023 |